Celltrove’s Strategic Investment in Oryxion to Strengthen Data-Centric Clinical Research Capabilities

We’re excited to share a major milestone in our journey. Celltrove Ventures Pte Ltd, Singapore has made a strategic investment in Oryxion Solutions Pvt. Ltd., India, a full-spectrum Data Contract Research Organization (CRO).

This partnership brings together Celltrove’s strengths in AI-driven, globally integrated clinical trial innovation with Oryxion’s precision in clinical data services—including Clinical Data Management, Statistical Programming, Biostatistics, Medical Writing, Regulatory Affairs, and Data Visualization.

Together, we aim to:
• Deliver end-to-end data support, from protocol development to regulatory submission
• Leverage AI, statistical modeling, and real-world evidence to unlock stronger insights
• Expand global scalability for multi-country trial execution with local expertise

“Oryxion has built a strong reputation for operational excellence in clinical data—delivering accuracy, compliance, and actionable insight in real-time,” said Bhavesh Acharya, Founder & Director of Celltrove.

“We’re excited to collaborate with Celltrove to scale our impact across more sponsors and geographies,” added Shabbir Bookseller, Founder & CEO of Oryxion.

This partnership is rooted in a shared vision: advancing clinical research through innovation, quality, and technology to improve patient outcomes. With Celltrove’s smart workflows, 360-degree data integration, and global talent—combined with Oryxion’s domain expertise and submission-ready execution—we are positioned to transform the future of data in clinical trials.